Noggin
Latest Information Update: 21 Aug 2007
At a glance
- Originator Regeneron Pharmaceuticals
- Class Carrier proteins
- Mechanism of Action Bone morphogenetic protein-4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Fibrodysplasia ossificans progressiva
Most Recent Events
- 27 Nov 2000 Preclinical development for Fibrodysplasia ossificans progressiva in USA (unspecified route)